HVTN 204 & PAVE 100 Vaccine Candidates = VRC Candidates Koleka Mlisana, MB,ChB Centre for the AIDS Programme of Research in South Africa (CAPRISA) Minister of Health Meeting, Pretoria 14 November 2007 VRC Candidate HIV Vaccine Months 0 1 2 3 6 9 12 CMV-R promoter Env A rAd5 Env B Env A Env C Env B gag B Env C pol B gag/pol B nef B VRC and Merck Vaccine Candidates Category VRC product - PAVE 100 Merck Product – STEP Heterologous vector Repeated dosing with Schedule prime-boost homologous vector 6 DNA plasmids Components 3 rAd5 vectors 4 rAd5 vectors E1, E3, E4-deleted, 293- rAd5 vector E1-deleted; PerC.6 ORF6 Antigens Envelope, Gag, Pol, Nef Gag, Pol Nef HIV subtypes A, B, C B DNA by Biojector Delivery rAd5 by needle and rAd5 by needle and syringe syringe Differences in VRC and Merck Clinical Products VRC Months 0 1 2 3 6 9 12 Only common constituent: Ad Gag-Pol (no Nef) <1 of 22 injected components Merck Months 0 1 2 3 6 9 12 Summary of Distinctions Between VRC and Merck AIDS Vaccines 1. Different type of immunization - DNA/DNA/DNA/Ad vs. Ad/Ad/Ad. 2. Differences in inserts in the vaccine-inclusion of Env A, B, C. 3. Qualitative and quantitative differences in the type of T cell immunity induced by the vaccine. 4. Alternative biology/construction of Ad5 vector. 5. Prolonged survival and reduction in viral load for >100 days in the more rigorous SIVmac239 challenge model in contrast to the Merck vaccine that showed no efficacy.
Pages to are hidden for
"HVTN 204 _amp; PAVE 100 Vaccine Candidates = VRC Candidates"Please download to view full document